clinical trial · NCT01471925
Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC
Eurofarma Laboratorios S.A.·phase3·withdrawn
Gastroesophageal Reflux DiseaseNexium®Esomeprazol (40mg) + Sodium Bicarbonate (721mg)
brief summary
A phase III, randomized, open-label, superiority study comparing the incremental product esomeprazole associated with sodium bicarbonate made by Eurofarma and Nexium® in the treatment of gastroesophageal reflux disease. The study will enroll 94 patients in each arm (total of 188 patients).
started
—
primary completion
—
completion
—
last updated
Apr 1, 2025
official title
A Phase III, Randomized, Open-label, Superiority Study Comparing the Incremental Product Esomeprazole Associated With Sodium Bicarbonate Made by Eurofarma and Nexium® in the Treatment of Gastroesophageal Reflux Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol